- Home
- OCSL vs AGIO Comparison
OCSL vs AGIO Comparison
Compare OCSL & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- AGIO
- Stock Information
- Founded
- OCSL 2007
- AGIO 2007
- Country
- OCSL United States
- AGIO United States
- Employees
- OCSL N/A
- AGIO N/A
- Industry
- OCSL Finance: Consumer Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- AGIO Health Care
- Exchange
- OCSL Nasdaq
- AGIO Nasdaq
- Market Cap
- OCSL 1.2B
- AGIO 1.4B
- IPO Year
- OCSL 2008
- AGIO 2013
- Fundamental
- Price
- OCSL $14.12
- AGIO $36.07
- Analyst Decision
- OCSL Hold
- AGIO Buy
- Analyst Count
- OCSL 7
- AGIO 6
- Target Price
- OCSL $16.00
- AGIO $58.60
- AVG Volume (30 Days)
- OCSL 674.0K
- AGIO 524.8K
- Earning Date
- OCSL 08-05-2025
- AGIO 07-31-2025
- Dividend Yield
- OCSL 11.37%
- AGIO N/A
- EPS Growth
- OCSL N/A
- AGIO N/A
- EPS
- OCSL 0.11
- AGIO 11.45
- Revenue
- OCSL $353,866,000.00
- AGIO $37,035,000.00
- Revenue This Year
- OCSL N/A
- AGIO $22.30
- Revenue Next Year
- OCSL N/A
- AGIO $219.19
- P/E Ratio
- OCSL $129.50
- AGIO $3.15
- Revenue Growth
- OCSL N/A
- AGIO 25.96
- 52 Week Low
- OCSL $12.50
- AGIO $23.42
- 52 Week High
- OCSL $18.87
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- OCSL 53.19
- AGIO 62.76
- Support Level
- OCSL $13.47
- AGIO $32.87
- Resistance Level
- OCSL $14.03
- AGIO $35.85
- Average True Range (ATR)
- OCSL 0.24
- AGIO 1.38
- MACD
- OCSL 0.02
- AGIO -0.05
- Stochastic Oscillator
- OCSL 59.29
- AGIO 76.58
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.